Table 3:
Comparing risks of outcome events within 28-days after a positive test between sotrovimab/molnupiravir versus untreated patients in the OpenSAFELY-UKRR dataset.
| Outcomes | HR (95% CI) for sotrovimab (ref = untreated) | P-value | HR (95% CI) for molnupiravir (ref = untreated) | P-value |
|---|---|---|---|---|
| 28-day COVID-19-related hospitalisation/death | ||||
| Model 1 | 0.38 (0.23–0.63) | <.001 | 0.94 (0.51–1.74) | .844 |
| Model 2 | 0.33 (0.20–0.55) | <.001 | 0.79 (0.43–1.45) | .443 |
| Model 3 | 0.38 (0.23–0.63) | <.001 | 0.79 (0.43–1.47) | .463 |
| Model 4 | 0.38 (0.23–0.63) | <.001 | 0.81 (0.44–1.49) | .492 |
| 28-day all-cause hospitalisation/death | ||||
| Model 1 | 0.74 (0.59–0.92) | .008 | 1.01 (0.70–1.44) | .975 |
| Model 2 | 0.74 (0.59–0.94) | .012 | 1.00 (0.70–1.44) | .995 |
| Model 3 | 0.78 (0.61–0.98) | .037 | 1.05 (0.73–1.50) | .810 |
| Model 4 | 0.78 (0.62–0.98) | .039 | 1.07 (0.75–1.54) | .704 |
In this analysis, 4588 untreated patients, 1624 sotrovimab users and 439 molnupiravir users were included (after excluding those whose positive test date was missing or outside of the study period). Model 1 adjusted for age and sex and stratified by region; Model 2 additionally adjusted for high-risk cohort categories, KRT modality and duration; Model 3 additionally adjusted for ethnicity, IMD quintiles, vaccination status, calendar date; and Model 4 additionally adjusted for BMI category, diabetes, hypertension, chronic cardiac and respiratory diseases.